Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer

Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer ORIGINAL INVESTIGATION Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer Eunyoung Cho, ScD; Gary Curhan, MD, ScD; Susan E. Hankinson, ScD; Philip Kantoff, MD; Michael B. Atkins, MD; Meir Stampfer, MD, DrPH; Toni K. Choueiri, MD Background: Epidemiologic data suggest that analge- of nonaspirin NSAIDs was associated with an increased sic use increases the risk of renal cell cancer (RCC), but RCC risk; the pooled multivariate relative risk was 1.51 few prospective studies have been published. We inves- (95% confidence interval, 1.12-2.04) at baseline. The ab- tigated the association between analgesic use and RCC solute risk differences for users vs nonusers of nonaspi- in 2 large prospective studies. rin NSAIDs were 9.15 per 100 000 person-years in women and 10.92 per 100 000 person-years in men. There was Methods: We examined the relationship between an- a dose-response relationship between duration of non- algesic use and RCC risk in the Nurses’ Health Study and aspirin NSAID use and RCC risk; compared with non- the Health Professionals Follow-up Study. Use of aspi- regular use, the pooled multivariate relative risks were rin, other nonsteroidal anti-inflammatory drugs (NSAIDs), 0.81 (95% confidence interval, 0.59-1.11) for use less than and acetaminophen was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer

Loading next page...
 
/lp/american-medical-association/prospective-evaluation-of-analgesic-use-and-risk-of-renal-cell-cancer-p878KgLq7V
Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2011.356
pmid
21911634
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Prospective Evaluation of Analgesic Use and Risk of Renal Cell Cancer Eunyoung Cho, ScD; Gary Curhan, MD, ScD; Susan E. Hankinson, ScD; Philip Kantoff, MD; Michael B. Atkins, MD; Meir Stampfer, MD, DrPH; Toni K. Choueiri, MD Background: Epidemiologic data suggest that analge- of nonaspirin NSAIDs was associated with an increased sic use increases the risk of renal cell cancer (RCC), but RCC risk; the pooled multivariate relative risk was 1.51 few prospective studies have been published. We inves- (95% confidence interval, 1.12-2.04) at baseline. The ab- tigated the association between analgesic use and RCC solute risk differences for users vs nonusers of nonaspi- in 2 large prospective studies. rin NSAIDs were 9.15 per 100 000 person-years in women and 10.92 per 100 000 person-years in men. There was Methods: We examined the relationship between an- a dose-response relationship between duration of non- algesic use and RCC risk in the Nurses’ Health Study and aspirin NSAID use and RCC risk; compared with non- the Health Professionals Follow-up Study. Use of aspi- regular use, the pooled multivariate relative risks were rin, other nonsteroidal anti-inflammatory drugs (NSAIDs), 0.81 (95% confidence interval, 0.59-1.11) for use less than and acetaminophen was

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Sep 12, 2011

References